StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) bonds

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.99−0.01 (-0.25%)

Close on Nov 18, 2026Market cap $1.30BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$49.26M
Long-term debt
Net debt
-$406.15M
After $455.41M of cash
Implied interest rate
0.13%
FY2025 interest ÷ average debt
Interest coverage
-1753.9×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Notes and loans outstanding

As tagged in Taysha Gene Therapies's 10-Q for the period ended Jun 30, 2026

Taysha Gene Therapies's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawnExpires
2023 Trinity Term Loan Agreement$40.00M–Nov 13, 2028
2025 Trinity Term Loan Agreement$50.00M$50.00MAug 1, 2030

See a number that looks wrong?